Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Propel Health Communications, a 2025 MM+M Agency 100 honoree, hired Christopher Thorn as SVP, creative director and Lauren Schulz as SVP of client services. DiaMedica announced the appointment of ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

The demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplant procedures, driven by the growing incidence of ...

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

Portfolio Receipts was $727 million in the second quarter of 2025, an increase of 20% compared to $608 million in the second quarter of 2024, primarily driven by the same Royalty Receipts increases ...

Discover key insights from Supernus Pharmaceuticals' Q2 2025 earnings, including revenue growth, new product launches, the Sage Therapeutics ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

DelveInsight's TYK2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis ...